Cationic ultrasound microbubble contrast agent and preparation method thereof
By combining guanidine-modified polylysine with lipid materials to form cationic ultrasonic microbubble contrast agents, combined with low-intensity ultrasonic targeting technology, the existing ultrasonic microbubble contrast agents have low gene transfection efficiency and short in vivo circulation time. The problem of this achieves efficient gene transfection and reduced cytotoxicity.
Patent Information
- Application Number
- CN202311653857.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-12-05
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2043-12-05
AI Technical Summary
The existing ultrasonic microbubble contrast agents have low gene transfection efficiency and short in vivo circulation time, and traditional liposome transfection reagents are expensive and cytotoxic.
Polylysine modified with guanidine group is combined with lipid materials to form cationic ultrasonic microbubble contrast agent, forming microbubble structures through electrostatic adsorption and oscillation, and combining low-intensity focused ultrasonic targeted microbubble blasting technology to promote the entry of therapeutic genes into cells .
It improves gene transfection efficiency, reduces cytotoxicity, prolongs the circulation time of microvesicles in the body, and reduces the cost of transfection reagents.
Smart Images

Figure HDA0004588248390000011 
Figure HDA0004588248390000012 
Figure HDA0004588248390000021
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of synthetic contrast agents, and specifically relates to a cationic ultrasound microbubble contrast agent and a preparation method thereof. Background Art
[0002] Microbubbles are small bubbles with a stable encapsulating shell and a diameter of the order of micrometers. Compared with normal-sized bubbles, microbubbles have a larger specific surface area, higher gas dissolution rate, longer liquid residence time and better surface adsorption capacity, and therefore have wide applications in many fields such as water treatment, medical treatment, food technology, and chemical industry. In particular, microbubbles play an increasingly important role in the biomedical field, including ultrasound imaging, drug delivery systems, biosensing, ultrasound-targeted microbubble bursting, and sonogenetics. For example, air microbubbles have long been used as ultrasound contrast agents for clinical diagnosis of vascular diseases such as thrombosis and tumors due to their high acoustic scattering properties and nonlinear interaction with ultrasound. However, air microbubbles, including lipid air microbubbles, polymer air microbubbles, and hard protein template microbubbles, do have several limitations. The main disadvantage of such self-assembled microbubbles is their low stability in aqueous solution, which is caused by the high solubility of air in water and the high Laplace pressure. Therefore, in order to obtain more stable microbubbles, great efforts have been made to identify alternative gases with low solubility in water, such as sulfur hexafluoride and perfluoropropane. Some ultrasound contrast agents have been reviewed by the Food and Drug Administration (FDA) and are now used in clinical practice, such as Sonovue, Definity, Optison, etc. These ultrasound contrast agents can meet the requirements for most organ imaging and are currently the most commonly used ultrasound contrast agents in clinical practice. Among them, sulfur hexafluoride microbubbles, as the most commonly used ultrasound contrast agent in clinical practice in China, are approved worldwide for use in the abdomen, breast, thyroid, cardiovascular and other parts. With the continuous development of ultrasound diagnosis and treatment technology, higher and newer requirements have been put forward for ultrasound contrast agents. Therefore, the replacement of ultrasound contrast agents is also getting faster and faster.
[0003] With the cross-development of ultrasound medicine and modern molecular biology, more and more scholars are committed to carrying therapeutic substances such as drugs and genes on ultrasound microbubbles, or connecting targeted substances such as molecular probes on the surface of microbubbles, so as to achieve effective diagnosis and effectively improve the treatment effect of diseases. Ultrasound-targeted microbubble bursting technology is a new type of gene and drug delivery technology. Its principle is to use microbubbles as carriers to emit ultrasound waves of different intensities at designated locations. When the ultrasound intensity reaches the threshold of microbubble bursting, the microbubbles in the blood rupture, generating microjets and shock waves to cause reversible or irreversible perforations on the surrounding vascular walls or cell membrane surfaces, damaging the vascular endothelial barrier, thereby increasing vascular permeability, increasing the dose of exogenous substances reaching specific locations, and exerting corresponding biological effects. This method has the advantages of targeted, fixed-point, and visualized gene delivery, and is one of the most promising methods for achieving gene targeted delivery. Despite this, the strategy of ultrasound-targeted microbubble bursting gene delivery using traditional ultrasound microbubble contrast agents can only perform cavitation perforation of cell membranes to achieve the delivery of exogenous genes from extracellular to intracellular, resulting in a generally low efficiency of gene transfection. Therefore, designing ultrasound microbubble contrast agents with their own gene transfection function and combining them with ultrasound targeted microbubble blasting technology is expected to achieve gene transfection efficiency.
[0004] Liposome transfection reagents themselves can cause changes in the expression of certain genes, thus affecting the objectivity of transfection experiment results. Currently, liposome transfection reagents on the market are relatively expensive. Therefore, the development of non-liposomal transfection reagents with domestic core technologies can effectively solve problems such as high cost and certain cytotoxicity.
[0005] In view of the problems of low gene transfection efficiency and short in vivo circulation time of existing ultrasound microbubble contrast agents, the present invention provides a novel cationic polymer ultrasound microbubble contrast agent and a preparation method thereof. Summary of the invention
[0006] The present invention uses a polymer to bind to the surface of microbubbles to form a cationic ultrasound contrast agent. The cationic ultrasound contrast agent has a gene transfection function and also has the dual functions of delivering RNA, plasmid DNA and ultrasound contrast. At the same time, the cationic ultrasound contrast agent is combined with the cavitation effect of low-intensity focused ultrasound targeted microbubble explosion technology to promote the carried therapeutic gene to enter the cell and improve the transfection efficiency.
[0007] In a first aspect, the present invention provides a cationic ultrasound microbubble contrast agent, which contains a polymer, a lipid material and a gas, wherein the polymer is bound to the lipid material by electrostatic adsorption, and then oscillated and a gas is added to form a microbubble structure; the polymer is guanidine-modified polylysine (PLL-Gly), polylysine and / or mPEG-L-lysine, and the guanidine group is selected from one or more of guanidinoacetic acid, guanidine propionate and guanidinobutyric acid.
[0008] Furthermore, the guanidine-modified polylysine is obtained by condensing polylysine (PLL) with the amide of a guanidine-containing compound.
[0009] Furthermore, the lipid material is selected from one or more of 1,2-didocosyl-sn-glycerol-3-phosphocholine (DBPC), 1,2-dipalmitoyl-sn-glycerol-3-phosphocholine (DPPC), 1,2-docosyl-sn-glycerol-3-phosphocholine (DLPC), 1,2-arachidonylphosphatidylcholine (DAPC), 1,2-dipalmitoyl-sn-glycerol-3-phosphatidic acid sodium salt (DPPA), dipalmitoylphosphatidylethanolamine (DPPE), 1,2-dipalmitoylphosphatidylethanolamine-polyethylene glycol-carboxyl (DSPE-PEG2000-COOH), biotinylated DSPE-PEG2000 (DSPE-PEG2000-Biotin), and maleimide DSPE-PEG2000 (DSPE-PEG2000-Mal).
[0010] Furthermore, the gas added during oscillation is perfluoropropane or sulfur hexafluoride, and a microbubble structure is formed after oscillation.
[0011] In a second aspect, the present invention provides a method for preparing a cationic ultrasound microbubble contrast agent, the method comprising the following steps:
[0012] S1.Synthetic polymers:
[0013] S01. The benzyloxycarbonyl-L-lysine cyclic anhydride (Lys-NCA) is reacted with diethylenetriamine in a DMF solution to generate triamine-terminated N(ε)-benzyloxycarbonyl-L-lysine;
[0014] S02. Triamine-terminated N(ε)-benzyloxycarbonyl-L-lysine reacts with hydrobromic acid / acetic acid in CF3COOH solution to generate PLL-DLA;
[0015] S03. Adding carbodiimide (EDC) and N-hydroxysulfosuccinimide (NHS) to PLL-DLA, and then adding a guanidine compound to the system, reacting at room temperature, dialyzing and freeze-drying to obtain polylysine (PLL-Gly);
[0016] S2. The polylysine prepared in S1 is combined with a lipid material by electrostatic adsorption; the lipid material is selected from one or more of 1,2-didocayl-sn-glycerol-3-phosphocholine (DBPC), 1,2-dipalmitoyl-sn-glycerol-3-phosphocholine (DPPC), 1,2-didocayl-sn-glycerol-3-phosphocholine (DLPC), 1,2-arachidonylphosphatidylcholine (DAPC), 1,2-dipalmitoyl-sn-glycerol-3-phosphatidic acid sodium salt (DPPA), dipalmitoylphosphatidylethanolamine (DPPE), 1,2-dipalmitoylphosphatidylethanolamine-polyethylene glycol-carboxyl (DSPE-PEG2000-COOH), biotin phthalated DSPE-PEG2000 (DSPE-PEG2000-Biotin), and maleimide DSPE-PEG2000 (DSPE-PEG2000-Mal).
[0017] S3. The polylysine bound to the lipid material is shaken and gas is added to form a microbubble structure.
[0018] Furthermore, the microbubbles described in S2 are prepared by adding the polymer PLL-Gly and the lipid materials DPPC (DAPC, DBPC, DLPC), DPPE, DPPA, DSPE-PEG2000-COOH (DSPE-PEG2000-Biotin, DSPE-PEG2000-Mal) into chloroform in different mass ratios, and after uniform dispersion, the organic solvent is dried by nitrogen to obtain a milky white lipid suspension.
[0019] Furthermore, the ratio of the polymer: lipid material: chloroform: nitrogen: organic solvent is (5-15): (60-100): (10-30): (20-50): (10-30), and the volume ratio of the added solvent is (8-15): (1-2): (1-3).
[0020] Furthermore, the ratio of the polymer: lipid material: chloroform: nitrogen: organic solvent is 10:80:20:35:20, and the volume ratio of the added solvent liquid is 12:1:3.
[0021] Furthermore, the microbubbles described in S3 are prepared by transferring the lipid solution obtained in S2 into a container, sealing it, evacuating it, exhausting the air in the suspension container, injecting perfluoropropane or sulfur hexafluoride into the container, and shaking the container in a mechanical oscillator to complete the microbubble preparation.
[0022] In a third aspect, the present invention provides an application of a cationic ultrasound microbubble contrast agent in gene transfection, wherein the application includes promoting the carried therapeutic gene to enter cells to improve transfection efficiency.
[0023] Furthermore, the therapeutic gene includes RNA and DNA. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 . Schematic diagram of the preparation process of PLL-Gly-MB, (a) the preparation process of PLL-Gly polymer, (b) the preparation process of PLL-Gly liposomes and the schematic diagram of inflation under vacuum to form PLL-Gly-MB;
[0025] Figure 2 .The chemical structure and 1H-NMR of PLL-Gly;
[0026] Figure 3 . (a) PLL-Gly liposomes and (b) PLL-Gly-MB microbubbles, their physical images, hydrodynamic particle size and Zeta potential;
[0027] Figure 4 Optical images of PLL-Gly-MB microbubbles formed after the PLL-Gly lipid solution was inflated with sulfur hexafluoride for (a) 5 min and (b) 10 min.
[0028] Figure 5 . To evaluate the transfection performance of PLL-Gly-MB, PLL-Gly, PLL-Gly-MB or MB were transfected with a certain concentration of siRNA in different cells, and the cells were collected after ultrasound irradiation or not, and the expression of related proteins after transfection was investigated by WB experiment;
[0029] Figure 6 . To evaluate the transfection performance of PLL-Gly-MB, PLL-Gly-MB and a certain concentration of DNA were transfected into melanoma cells (A375 cells), and the expression of green fluorescent protein in the cells was observed using a fluorescence microscope;
[0030] Figure 7 .Cytocompatibility of PLL-Gly-MB, (a) Cell viability after culturing different types of cells with different concentrations of PLL-Gly-MB for 24 hours; (b) Cell viability after culturing normal vascular endothelial cells (HUVECs) with different transfection reagents and clinical liposome microbubbles for 24 hours;
[0031] Figure 8 .H&E staining of different organ tissues of normal mice after intravenous injection of different concentrations of PLL-Gly-MB dispersion;
[0032] Fig. 9. Investigation of the ultrasonic properties of PLL-Gly-MB, (a) in vitro ultrasonic images of PLL-Gly and PLL-Gly-MB, and ultrasonic images of (b) the liver and (c) the kidney of SD rats injected intravenously with PLL-Gly-MB dispersion before and after injection;
[0033] Fig.10 Bioluminescence images of mice at different time points after intramuscular injection of PLL-Gly-MB / luciferase-mRNA to detect the expression of luciferase in mice. DETAILED DESCRIPTION
[0034] The specific embodiments of the present invention are further described below. It should be noted that the description of these embodiments is used to help understand the present invention, but does not constitute a limitation of the present invention. In addition, the technical features involved in the embodiments described below can be combined with each other as long as they do not conflict with each other.
[0035] The experimental methods in the following examples are conventional methods unless otherwise specified, and the experimental materials used in the following examples are commercially available unless otherwise specified.
[0036] Example 1 Synthesis of transfection reagent
[0037] 1. Synthesis of guanidine-modified polylysine:
[0038] The preparation process of guanidine-modified polylysine comprises: 1. weighing a certain proportion of benzyloxycarbonyl-L-lysine cyclic anhydride (Lys-NCA), synthesizing polylysine ([C6H 12 N2O]n (n=25-60). A certain amount of benzyloxycarbonyl-L-lysine cyclic anhydride was dissolved in DMF, and a pre-prepared DMF solution of diethylenetriamine was added as an initiator, and magnetic stirring was performed at room temperature for a certain period of time.
[0039] The product was dialyzed and freeze-dried, then redissolved in trifluoroacetic acid, and a mixed solution of hydrobromic acid / acetic acid was added dropwise during stirring for reaction. Finally, the product was precipitated with anhydrous ether, filtered, dialyzed, and freeze-dried to obtain diamine-terminated polylysine (PLL-DLA).
[0040] 2. Dissolve the PLL-DLA obtained above into a dilute solution of a certain concentration, add EDC and NHS in a mass ratio of 1-3.5:1, and react for 1-3 hours. Then, add guanidine acetic acid, guanidine propionate or guanidine butyric acid to the system and react at room temperature for 6-12 hours. Then dialyze the reaction solution and freeze-dry it to obtain the product PLL-Gly. Use 1H-NMR to confirm the structure of the product. Figure 2 shown.
[0041] 2. Synthesis of PLL-Gly-MB:
[0042] Cationic polymer lipid microbubbles were prepared by mechanical oscillation.
[0043] (1) Preparation of polymer-modified lipids: PLL-Gly, DPPC (DAPC, DBPC, DLPC), DPPE, DPPA, DSPE-PEG2000-COOH (DSPE-PEG2000-Biotin, DSPE-PEG2000-Mal) are added to chloroform in different mass ratios, and after uniform dispersion, the organic solvent is blown dry by nitrogen gas in a ratio of 10: (60-100): (10-30): (20-50): (10-30). A certain volume of solvent solution (composed of PBS, propylene glycol, and glycerol in different volumes) is added to dissolve the lipids in a volume ratio of 8-15: 1: (1-3). If some large pieces of undissolved lipids are seen, dissolve them by ultrasonic heating to ensure that there is no undissolved lipid on the wall of the bottle. Finally, a milky white suspension is obtained as shown in the insert. Figure 3 The particle size and Zeta potential were measured by using a particle size and potential analyzer. Figure 3 As shown in a.
[0044] (2) Preparation of microbubbles: Transfer 1 mL of the lipid solution prepared above into a sterile vial, cover and seal each vial. Use a three-way tube to connect a syringe to draw a vacuum several times to expel the air from the bottle. Switch the three-way tube channel, install a 25 g needle connected to perfluoropropane or sulfur hexafluoride into the syringe, and pierce the septum cap until the pressure is balanced. Immediately add another needle without a syringe as an exhaust port, and exchange them sufficiently to ensure that the bottle is completely filled with gas. Place the bottle in a mechanical oscillator and shake it for a certain period of time to complete the microbubble preparation. Photos of the solution passing through microbubbles are shown below. Figure 3 As shown in b, the morphology of cationic ultrasound microbubbles was detected by inverted fluorescence microscopy. Figure 4 As shown, the particle size, potential and dispersion coefficient are measured as Figure 3 As shown in b.
[0045] like Figure 3 As shown in FIG. 1 , the synthesized PLL-Gly liposomes are milky white suspensions with an average hydrodynamic diameter of 1.04±0.23 μm and a surface charge of 13.9±1.2 mV. When the liposomes are inflated, the formed PLL-Gly-MBs are Figure 1As shown in the figure, after the microbubbles were left to stand, obvious bubbles could be observed above the suspension, proving the successful synthesis of the microbubbles. At the same time, its average hydrodynamic diameter increased to 2.52±0.36μm, and the surface charge was 16.4±2.3mV, indicating that the surface of the synthesized PLL-Gly-MB microbubbles had a high positive charge, and therefore was suitable for transfection of nucleic acid drugs such as RNA or DNA.
[0046] like Figure 4 As shown in the figure, the above method can be used to aerate PLL-Gly-MB to form micron bubbles with relatively uniform particle size, and the bubble diameter is about 2.2 μm, which is consistent with Figure 3 In addition, as the inflation time increases, the diameter of the microbubbles increases to a certain extent (the average diameter after inflation for 10 minutes is 2.6 μm), and the overall size range can be controlled within 2-6 μm. This size range will lay the foundation for subsequent ultrasound contrast imaging.
[0047] Example 2 Cell experiment The transfection performance of the synthesized PLL-Gly-MB microbubbles was determined:
[0048] The conventional transfection performance was determined by using different cells (including human renal epithelial cell line 293T, tumor cell MCF7, etc.). The specific cell transfection operation is as follows:
[0049] (1) The synthesized PLL-Gly-MB or polymer-free liposome microbubble dispersion is diluted to form a working solution.
[0050] (2) A certain amount of siRNA, mRNA or plasmid is added to the above working solution using a sterile pipette. Each group is placed on a shaker at a low speed and then allowed to stand at room temperature for a certain period of time to obtain a transfection complex.
[0051] (3) Add the transfection complex to the well plate or culture flask, move the culture dish back and forth, and mix thoroughly before subsequent cell manipulation.
[0052] (4) Cell culture: Different cell lines were purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences. Both cells were cultured in DMEM medium containing 10% fetal bovine serum, 1% penicillin and 1% streptomycin and maintained at 37°C and 5% CO2.
[0053] (5) After incubation with different microbubbles, the cells were washed with PBS three times, and then subjected to ultrasound irradiation. The ultrasound parameters were as follows: emission frequency of 0.5-2 MHz, sound pressure of 0.5 MPa, duration of 1-5 minutes, and duty cycle of 10-30%. Western Blot (WB, protein immunoblotting) was used as follows. Figure 5 As shown, Figure 6 The gene transfection efficiency was verified by fluorescence microscopy and other means.
[0054] like Figure 5 As shown, there was no obvious transfection result after the ultrasonic microbubble MB without cationic polymer was co-incubated with cells. In contrast, when the cells were treated with PLL-Gly-MB carrying siRNA, the expression of different genes (Mettl13 and HSP90) in various cells was significantly reduced. In addition, after a certain period of ultrasound irradiation, the expression of intracellular proteins was further reduced. The results show that PLL-Gly-MB can be used for siRNA transfection applications, and the combined use of ultrasound targeted microbubble blasting technology can further improve the efficiency of gene transfection.
[0055] An inverted fluorescence microscope was used to observe the GFP expression of A375 cells after cationic ultrasound microbubbles combined with ultrasound stimulation. Figure 6 As shown, the GFP protein expression level in the microbubble carrying plasmid DNA containing GFP reporter gene+US group was significantly higher than that in the group without ultrasound stimulation or microbubble transfection alone, proving that the prepared PLL-Gly-MB can be used as a universal gene transfection ultrasound microbubble.
[0056] Example 3 Biosafety Testing
[0057] Safety testing at the cell level: The cytotoxicity was evaluated using the commonly used CCK-8 method. Different cells cultured in advance were digested with trypsin and then plated at a density of 5×10 3 Cells / well were inoculated into 96-well plates containing 100 μL DMEM medium and cultured for 24 hours. After the cells were completely attached, the medium was removed and 100 μL of fresh medium containing different concentrations of cationic microbubbles was added. After re-culturing for 24 hours, the cell viability was determined by CCK-8 method. Six replicate wells were set for each group of samples, and each sample was measured three times in parallel. At the same time, the absorbance of the control group was used as the blank control to calculate the cell survival rate.
[0058] like Figure 7 As shown in a, even after treatment with a high concentration of 200 μg / mL PLL-Gly-MB, the cell survival rate was still above 80%. Figure 7 b It can be seen that at the same concentration, the cytotoxicity of PLL-Gly-MB is similar to that of MB, showing similar cell compatibility. Compared with other commonly used commercial transfection reagents (PEI-25KDa, Lipo3000), PLL-Gly-MB has lower toxicity, indicating its good cell compatibility.
[0059] Experimental conclusion: The synthesized PLL-Gly-MB microbubbles have good cell compatibility within a certain concentration range and are suitable for cell experiments.
[0060] Safety testing at the animal level: All animal experiments were conducted in accordance with the guidelines of the Experimental Animal Care and Use Committee of the Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine. Balb / c mice were purchased from Nanjing Pengsheng Biotechnology Co., Ltd. First, normal mice were intravenously injected with a PBS solution of PLL-Gly-MB (1.5 mg / mL), and different tissues were taken for pathological sections after injection to verify the biosafety of the transfection reagent.
[0061] like Figure 8 As shown, after intravenous injection of a high concentration of PLL-Gly-MB PBS solution, different tissues (heart, liver, spleen, lung, and kidney) were taken for H&E staining, and no obvious apoptotic or necrotic cells were observed in each organ, proving that the prepared microbubbles have good biosafety and are suitable for in vivo experiments.
[0062] Example 4 Applicability Evaluation
[0063] Next, the imaging performance of the material was evaluated. PLL-Gly-MB dispersions with concentrations of 0.5 and 2 mg / mL were prepared respectively. The sample was placed in a sample tube and connected to a small animal ultrasound imaging system (Vevo LAZR), and static ultrasound contrast images were collected in B mode and contrast mode, respectively. Among them, the mechanical index was set to 0.07 and the frequency was 40 MHz. At the in vivo level, SD mice were intravenously injected with a certain dose of PLL-Gly-MB PBS dispersion, connected to an ultrasound probe and a coupling agent, and ultrasound imaging of different parts was performed using the VevoLAZR ultrasound imaging system.
[0064] like Fig. 9 As shown in a, water and liposomes without encapsulated gas hardly produce any US signals in either B mode or CEUS mode. In contrast, PLL-Gly-MB produces obvious echo signals, proving that the prepared cationic microbubbles have good ultrasound contrast performance. Fig. 9 As shown in Figure b, after intravenous injection of PLL-Gly-MB PBS dispersion, obvious microbubble signals were observed in the liver of rats 10 seconds later. When the burst mode was used, obvious strong echo signals were generated. In addition, when the probe was moved to the kidney, microbubbles of a certain intensity were also observed. Fig. 9 As shown in c, it is demonstrated that the synthesized PLL-Gly-MB can be used for ultrasound contrast imaging applications at multiple sites in the body.
[0065] In order to detect the effect of PLL-Gly-MB for RNA transfection in vivo, PLL-Gly / mRNA complex was used for verification. BALB / c mice were injected with cationic microbubbles loaded with luciferase mRNA by intramuscular injection. Within a certain period of time, the mice were injected with luciferase substrate intraperitoneally and subjected to low-intensity ultrasound irradiation for 5-10 min (2.5 W / cm 2 ). This was then detected by in vivo fluorescence imaging of small animals.
[0066] like Fig.10 As shown in the figure, the fluorescence intensity in the abdominal cavity increases with time, reaching the highest level at 12h, and obvious fluorescence can still be observed at 24h, indicating that cationic microbubbles can effectively transfect mRNA into animals, thereby stimulating luciferase in the body. In addition, when combined with low-intensity focused ultrasound, more significant green fluorescence can be seen in the abdominal cavity. The above results prove that the prepared PLL-Gly-MB microbubbles can be used for in vivo mRNA delivery, and the combination with low-intensity ultrasound can further enhance the in vivo transfection effect.
Claims
1. A cationic ultrasound microbubble contrast agent, comprising a polymer, a lipid material and a gas, wherein the polymer is guanidine-modified polylysine (PLL-G1y), and the guanidine-modified polylysine is obtained by amide condensation reaction of polylysine (PLL) and a guanidine-containing compound; the lipid material is 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dipalmitoyl-sn-glycero-3-phosphatidic acid sodium salt (DPPA), dipalmitoylphosphatidylethanolamine (DPPE), 1,2-dipalmitoylphosphatidylethanolamine-polyethylene glycol-carboxyl (DSPE-PEG2000-COOH); The preparation method of the cationic ultrasound microbubble contrast agent comprises the following steps: S1. Synthetic polymers: S01. The benzyloxycarbonyl-L-lysine cyclic anhydride (Lys-NCA) is reacted with diethylenetriamine in a DMF solution to generate triamine-terminated N(ε)-benzyloxycarbonyl-L-lysine; S02. Triamine-terminated N(ε)-benzyloxycarbonyl-L-lysine in CF 3 COOH solution reacts with hydrobromic acid / acetic acid to generate PLL-DLA; S03. Adding carbodiimide (EDC) and N-hydroxysulfosuccinimide (NHS) to PLL-DLA, and then adding a guanidine compound to the system, reacting at room temperature, dialyzing and freeze-drying to obtain guanidine-modified polylysine (PLL-Gly); S2. The guanidine-modified polylysine prepared in S1 is combined with the lipid material by electrostatic adsorption; the polymer PLL-G1y and the lipid material are added to chloroform in different mass ratios, and after uniform dispersion, the organic solvent is blown dry by nitrogen, and a certain volume of a solvent solution composed of PBS, propylene glycol, and glycerol is added to dissolve the lipid to obtain a milky white lipid suspension, wherein the ratio of the polymer: lipid material: chloroform: nitrogen is (5-15): (60-100): (10-30): (20-50), and the volume ratio of PBS, propylene glycol, and glycerol in the added solvent solution is (8-15): (1-2): (1-3); S3. The lipid solution obtained in S2 is transferred to a container, sealed, vacuumed, and the air in the suspension container is exhausted. Sulfur hexafluoride is injected into the container, and the container is placed in a mechanical oscillator and shaken to complete the microbubble preparation.
2. Use of the cationic ultrasound microbubble contrast agent as claimed in claim 1 in the preparation of a gene transfection preparation, wherein the use comprises promoting the carried therapeutic gene to enter cells to improve transfection efficiency.
3. Use of the cationic ultrasound microbubble contrast agent as claimed in claim 1 in the preparation of a gene transfection preparation, It is characterized in that The gene includes RNA and DNA.
